Andrew Witty, UnitedHealth CEO, said the move will remove an excuse other players use to blame Optum Rx for high drug costs.

Our narrow economic moat rating for UnitedHealth Group reflects our generally narrow-moat view of the US health insurance and PBM industries that includes an unclear outlook for economic profitability ...

UnitedHealth reported fourth-quarter results on Thursday that reflected persistent challenges for the health insurance sector ...

FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands ...

CVS Health shares are trading lower by 2.7% during Thursday's session. Shares of insurers and pharmacy benefit manager stocks ...

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter ...

Wedmont Private Capital lessened its holdings in shares of CVS Health Co. (NYSE:CVS – Free Report) by 21.5% in the fourth ...

Claro Advisors LLC trimmed its position in shares of CVS Health Co. (NYSE:CVS – Free Report) by 59.7% during the fourth ...

Following a rough fourth quarter, we see the healthcare sector overall as undervalued, with a median discount to our fair ...

Report reveals big pharma middlemen inflating drug prices, reaping billions in excess revenue. • The Federal Trade Commission (FTC) released a report showing that pharmacy benefit managers (PBMs) ...